Kraj: Nowa Zelandia
Język: angielski
Źródło: Medsafe (Medicines Safety Authority)
Loratadine 10mg; ; ;
Apotex NZ Ltd
Loratadine 10 mg
10 mg
Tablet
Active: Loratadine 10mg Excipient: Croscarmellose sodium Hydrated silica Lactose monohydrate Magnesium stearate Microcrystalline cellulose
Blister pack, PVC/Al, 15 tablets
Pharmacy only
Pharmacy only
Morepen Laboratories Limited
APO-LORATADINE is indicated for the relief of: · Symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching, and ocular itching and burning. · Symptoms and signs of chronic urticaria and other allergic dermatological disorders.
Package - Contents - Shelf Life: Blister pack, PVC/Al - 15 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, PVC/A - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, HDPE - 100 tablets - 36 months from date of manufacture stored at or below 25°C
2001-05-07
NEW ZEALAND DATA SHEET APO-LORATADINE Loratadine 10mg Tablets Please refer to Medsafe website ( www.medsafe.govt.nz ) for the most recent datasheet Page 1 PRESENTATION APO-LORATADINE 10mg tablets are white, oval tablets (7.6mm x 5.1mm), deep-scored, engraved ‘LO’ over ‘10’ on one side, ‘APO’ on the other. Each tablet contains 10mg of loratadine and typically weighs 105mg and INDICATIONS APO-LORATADINE is indicated for the relief of: Symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching, and ocular itching and burning. Symptoms and signs of chronic urticaria and other allergic dermatological disorders. DOSAGE AND ADMINISTRATION ADULTS AND CHILDREN 12 YEARS OF AGE AND OVER: One APO-LORATADINE tablet once daily. CHILDREN 2 – 12 YEARS OF AGE: Bodyweight >30kg: one APO-LORATADINE tablet once daily. Bodyweight <30kg: Half an APO-LORATADINE tablet once daily. CONTRAINDICATIONS APO-LORATADINE is contraindicated in patients who have shown hypersensitivity or idiosyncrasy to the drug or its components. WARNINGS AND PRECAUTIONS Do not exceed the recommended dose. In an 18-month carcinogenicity study in mice and a 2-year study in rats, loratadine was administered in the diet at doses up to 12 mg/kg (mice) and 25 mg/kg (rats). Male mice given 12 mg/kg had a significantly higher incidence of hepatocellular tumors. The 2-year study in rats showed no increase in the incidence of carcinogenicity in doses up to 25 mg/kg/day. In a 17-month study in monkeys, loratadine demonstrated no functional impairment of the immune system as indicated by mortality, peripheral leucocyte count or incidences of inflammatory reactions, autoimmune disease and malignancy. Specific studies investigating the effect of loratadine on immune function Przeczytaj cały dokument